MENU
Now in various stages of development, the products in our pipeline are focused on rare autoinflammatory and autoimmune diseases with unmet needs, and have the potential to address multiple therapeutic areas.
| Program & Target | Therapeutic Area | Preclinical | Phase 1 | Phase 2 | Phase 3 | Mkt | Rights | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Rilonacept IL-1α & IL-1β | Recurrent pericarditis (breakthrough therapy designation) |
Mid Phase 3 | Worldwide (excluding the Middle East and North Africa) | |||||||
| Mavrilimumab GM-CSFRα | Giant cell arteritis | Phase 2 | Worldwide | |||||||
| KPL-716 OSMRβ | Prurigo nodularis | Phase 2 | Worldwide | |||||||
| Multi-indication pilot study in diseases with a chronic pruritic component | End Phase 1 | Worldwide | ||||||||
| KPL-404 CD40 | T-cell dependent, B-cell–mediated indications | Phase 1 | Worldwide | |||||||
| KPL-045 CD30L | T-cell dependent, B-cell–mediated indications | Preclin | Worldwide | |||||||
